

Unicycive Therapeutics, Inc.  
4300 El Camino Real, Suite 210  
Los Altos, CA 94022

August 1, 2023

**VIA EDGAR**

United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: Alan Campbell

**Re: Unicycive Therapeutics, Inc.  
Registration Statement on Form S-3  
File No. 333-273221  
Filed July 13, 2023**

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the "Act"), Unicycive Therapeutics, Inc. (the "Company") respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 9:00 a.m., Eastern Daylight Time, on Thursday, August 3, 2023, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Please notify Jeffrey Fessler of Sheppard Mullin Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the registration statement has been declared effective pursuant to this acceleration request.

Very truly yours,

**UNICYCIVE THERAPEUTICS, INC.**

By: /s/ Shalabh Gupta

Name: Shalabh Gupta

Title: Chief Executive Officer

cc: Jeffrey Fessler, Sheppard Mullin Richter & Hampton LLP